Investment Rating - The report upgrades the investment rating to "Strong Buy" with a target price of HKD 16.00, compared to the current price of HKD 12.45 [2][8]. Core Insights - The company reported a revenue of HKD 14.354 billion for 2025, representing a year-on-year growth of 9.97%, with Q4 revenue growth of 3.4% [8]. - Adjusted EBITDA for 2025 was HKD 2.05 billion, up 5.0% year-on-year, while adjusted net profit reached HKD 664 million, a 22.7% increase [8]. - The company is expected to continue its growth trajectory in 2026, with a focus on product innovation and market expansion, particularly in the Swisse brand and high-end infant formula [8]. - The debt structure is improving, with a reduction in total debt and interest expenses, which is anticipated to enhance overall profitability [8]. Financial Performance Summary - For 2025, the company achieved an adjusted EBITDA margin of 14.3%, with a net profit margin of 4.6% [8]. - The net leverage ratio decreased from 3.99x to 3.45x, indicating a stronger balance sheet [8]. - The company expects revenue growth in 2026 to be in the high single to low double digits, with adjusted net profit margin targets around 5% [8]. Business Segment Performance - The ANC segment generated revenue of HKD 6.946 billion in 2025, growing 3.7% year-on-year, with Swisse maintaining the top market share in China and Australia [8]. - The BNC segment saw a robust revenue increase of 20.0% year-on-year, reaching HKD 5.257 billion, driven by strong growth in high-end infant formula [8]. - The PNC segment reported revenue of HKD 2.150 billion, up 9.0% year-on-year, with Zesty Paws experiencing a 12.8% growth in North America [8].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.69 [6][4]. Core Insights - The company has shown robust performance driven by three main business segments: Adult Nutrition (ANC), Infant Nutrition (BNC), and Pet Nutrition (PNC). In 2025, the company achieved revenues of RMB 14.35 billion, net profit of RMB 200 million, and adjusted comparable net profit of RMB 660 million, reflecting year-on-year growth of 10.0%, a turnaround from loss, and an increase of 22.7% respectively [1][3]. - The company is expected to continue its steady growth in 2026, particularly in the ANC and PNC segments, with the infant formula business anticipated to recover further. The company is also focusing on debt reduction, having reduced total debt by over RMB 600 million during the year [1][4]. Summary by Relevant Sections Financial Performance - In 2025, the company reported a gross margin increase of 1.8 percentage points to 62.4%, driven by improved margins in the ANC and PNC segments and optimized procurement costs [3]. - The adjusted comparable EBITDA margin decreased by 0.7 percentage points to 14.3%, with variations across business segments: ANC at 19.9%, BNC at 11.4%, and PNC at 3.1% [3]. - The company ended 2025 with a cash balance exceeding RMB 1.7 billion and a net leverage ratio reduced from 3.99 times in 2024 to 3.45 times in 2025 [1][3]. Business Segment Performance - In 2025, the ANC segment revenue grew by 4.4%, with notable growth in the Chinese market at 13.3%, while the Australian and New Zealand market saw a decline of 21.8% due to a strategic reduction in purchasing business [2]. - The BNC segment showed significant recovery, with infant formula revenue increasing by 26.5% and probiotics and nutritional supplements for infants growing by 2.0% [2]. - The PNC segment reported a revenue increase of 8.7%, with growth in mainland China at 8.6% and North America at 7.8% [2]. Profit Forecast and Valuation - The profit forecast for 2026-2027 has been slightly raised, with expected net profits of RMB 730 million and RMB 860 million, representing increases of 13% and 16% respectively from previous estimates [4]. - The estimated EPS for 2026, 2027, and 2028 is projected at RMB 1.12, RMB 1.34, and RMB 1.48 respectively, with a reference PE ratio of 16x for 2026 [4][10].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.69 [6][4]. Core Views - The company has demonstrated stable operations driven by three main business segments: Adult Nutrition (ANC), Infant Nutrition (BNC), and Pet Nutrition (PNC). The revenue for 2025 is projected to be CNY 14.35 billion, with a year-on-year growth of 10.0% [1][2]. - The company has successfully turned around its net profit to CNY 2.0 billion in 2025, compared to a loss in the previous year, and adjusted net profit increased by 22.7% to CNY 6.6 billion [3][1]. - The company is expected to continue its steady growth in ANC and PNC segments, with the infant formula business anticipated to recover further [1][4]. Summary by Relevant Sections Financial Performance - In 2025, the company achieved revenues of CNY 14.35 billion, net profit of CNY 2.0 billion, and adjusted comparable net profit of CNY 6.6 billion, reflecting a year-on-year increase of 10.0%, a turnaround from loss, and a 22.7% increase respectively [1][3]. - The gross margin improved by 1.8 percentage points to 62.4% in 2025, driven by better margins in ANC and PNC segments [3]. - The company reduced its net leverage ratio from 3.99 times in 2024 to 3.45 times in 2025, with cash reserves exceeding CNY 1.7 billion at the end of 2025 [1][3]. Business Segment Performance - ANC revenue grew by 4.4% to CNY 69.5 billion, with strong performance in the Chinese market (+13.3%) but a decline in the Australian and New Zealand market (-21.8%) due to a strategic reduction in purchasing business [2]. - BNC revenue saw a significant recovery, with infant formula sales increasing by 26.5% and probiotics and nutritional supplements for infants growing by 2.0% [2]. - PNC revenue increased by 8.7%, with notable growth in the Chinese mainland (+8.6%) and North America (+7.8%) [2]. Profitability and Valuation - The adjusted comparable EBITDA margin decreased by 0.7 percentage points to 14.3% in 2025, with variations across business segments [3]. - The company has slightly raised its profit forecasts for 2026 and 2027, expecting net profits of CNY 7.3 billion and CNY 8.6 billion respectively, with an introduction of a 2028 forecast of CNY 9.6 billion [4]. - The target price of HKD 19.69 corresponds to a 16x PE ratio for 2026, reflecting a positive outlook based on comparable company valuations [4].

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1][10] - The leverage ratio decreased from 4x in 2024 to 3.045x in 2025, indicating improved financial health [1][45] - The adjusted EBITDA margin was reported at 14.3%, with a net profit growth rate of 22.7% [10][12] Business Segment Data and Key Metrics Changes - Swisse's revenue exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment growing by 17.12% [3][12] - The PNC business accounted for 15% of total revenue, marking a new milestone, with pet supplements achieving double-digit growth [3][12] Market Data and Key Metrics Changes - China remains the largest market, contributing over 70% of revenue with a growth of 17.5% [13] - North America accounted for 12.1% of revenue, growing by 7.5%, while the ANZ market decreased by 20.2% due to strategic adjustments [14][15] - Other markets grew by 14.7% year-on-year, indicating new growth momentum [15] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to enhance shareholder value and maintain a strong cash flow [4][29] - Focus on systematic innovation and consumer insights to drive product development and market expansion [6][9] - The strategy includes localization of supply chains and expansion into high-growth channels, particularly in Southeast Asia [29][30] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, emphasizing the importance of innovation and market adaptation [28][31] - The company aims to maintain a stable SG&A ratio while continuing to invest in new channels and product categories [65] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [22][75] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has contributed to the strong growth of IMF? - Management highlighted the strong formula of the upgraded IMF and the effective market launch strategies as key factors for growth [49][50] Question: What is the expansion plan for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [54][55] Question: What is the outlook for the Douyin channel and marketing expenses? - Management views Douyin as a critical channel for consumer education and sales, with plans to maintain a stable SG&A ratio while investing in new channels [60][65]

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1] - The leverage ratio has been reduced from 4x in 2024 to 3.045x in 2025 [1][45] - Adjusted EBITDA margin is reported at 14.3%, with adjusted net profit margin at 4.6% and net profit growth rate at 22.7% [10][32] Business Segment Data and Key Metrics Changes - Swisse revenue sales exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment achieving 17.12% growth [3] - The PNC business accounted for 15% of total revenue, marking a new milestone [3] Market Data and Key Metrics Changes - China remains the largest market, accounting for over 70% of revenue with a growth of 17.5% [13] - North America is the second largest market, contributing 12.1% of revenue with a 7.5% year-on-year growth [14] - The ANZ market accounted for 11% of revenue but saw a decrease of 20.2% due to strategic adjustments [14] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to return value to shareholders and consumers [4] - Focus on systematic innovation and consumer insights to drive growth, with new product launches across various segments [6][9] - Emphasis on expanding presence in high-growth channels, including Douyin and new retail [29] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum for 2026, with a focus on sustainable growth and healthy profitability [28][31] - The company aims to strengthen its leadership in core markets while expanding into new territories [29][30] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [19][22] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability efforts, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has been done right for IMF growth and market share? - Management highlighted strong product formulation and effective market strategies, leading to over 25% growth in IMF [50] - The company has gained market share from competitors, particularly in the super premium segment, increasing from 17.1% to 19.5% [53] Question: What are the expansion plans for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [55] Question: Insights on Douyin channel profitability and marketing expenses? - Management views Douyin as a crucial channel for consumer education and sales, balancing investments across various channels [61][62] - Marketing expenses are expected to remain stable while continuing to invest in new channels and product categories [66]

Core Viewpoint - The company is expected to achieve a revenue growth of 10% year-on-year in 2025, with projected revenues of 14.3 billion yuan and a net profit of 690 million yuan [1]. Group 1: Revenue Growth - All three business segments are anticipated to show strong growth in 2025. Specifically, ANC revenue is expected to grow in the mid-to-high single digits, while BNC and PNC revenues are projected to achieve low double-digit growth year-on-year [1]. - ANC segment is expected to benefit from increased demand for health products and related policy catalysts, with Swisse China projected to achieve double-digit growth in 2025. The official account indicates a 6% year-on-year increase in sales during the Double Eleven shopping festival, maintaining its position as the leader in the nutrition and health industry [1]. - BNC segment is projected to see over 20% revenue growth in 2025, primarily due to effective customer acquisition strategies, while probiotics and infant nutrition products are expected to stabilize with a significant reduction in decline [1]. - PNC segment is expected to continue double-digit growth in the U.S. market for Zesty Paws, contributing to overall PNC growth, while Solid Gold is anticipated to recover with high single-digit growth, with a narrowing decline in the U.S. market [1]. Group 2: Profitability and Margin - The EBITDA margin for 2025 is expected to align with market expectations, with ANC EBITDA margin remaining stable year-on-year. BNC EBITDA margin is projected to improve to low double digits due to sales improvements, while PNC EBITDA margin is expected to remain in the mid-single digits [2]. - Overall, the group’s EBITDA margin is anticipated to remain stable year-on-year in 2025. For 2026, ANC revenue is expected to achieve high single-digit growth, BNC revenue is projected to grow in the mid-single digits due to a high base, and PNC revenue is expected to continue double-digit growth [2]. Group 3: Profit Forecast and Valuation - The company is trading at 10-9 times the P/E ratio for 2026/2027. Given the strong performance of the milk powder segment, net profit estimates for 2025 and 2026 have been raised by 3% to 690 million yuan and 820 million yuan, respectively, with a profit forecast of 910 million yuan for 2027 [2]. - Considering the competitive nature of the industry, the target price is maintained at 17.7 HKD, corresponding to 13-11 times the P/E ratio for 2026/2027, indicating a 29% upside potential. The company maintains an outperform rating relative to the industry [2].

Core Insights - The nutrition and health industry is currently in an adjustment phase, with declines in infant formula, intensified competition in adult nutrition, and structural differentiation in the pet segment. Despite this, the company achieved a revenue of 10.805 billion yuan in the first three quarters, reflecting a year-on-year growth of 12.3%, indicating stability [1] Group 1: Company Growth Strategy - The core value of the company lies not in a single product explosion but in the establishment of a "whole family nutrition health ecosystem" across infant, adult, and pet segments, extending the consumer lifecycle [1] - The company leverages maternal and infant channels, content marketing, and a comprehensive domestic and international e-commerce system to create a wide-reaching touchpoint network [1] - In the adult segment, Swisse has established clear positioning through a high-end and youthful product matrix across multiple subcategories [1] Group 2: International Market Structure - The company's international layout consists of three layers: - Core driving market (China) accounts for over 70% and remains the growth engine [2] - Mature markets (Australia and New Zealand) show stable growth, with Swisse maintaining a leading position and achieving an 8.9% growth [2] - Expanding markets (Southeast Asia, Middle East, Italy, etc.) are experiencing double-digit growth, representing potential future waves over the next three to five years [3] Group 3: Supply Chain and Operational Resilience - The company's supply chain system is crucial for supporting multi-market operations, with six R&D centers and multiple production bases facilitating resource sharing and raw material interchange [3] - The resilience of the supply chain allows the company to maintain stable gross margins during cost fluctuations and ensures product quality consistency within a global traceability system [3] Group 4: Long-term Investment Value - The company possesses three long-term value points: - A multi-category structure that reduces cyclical risks [4] - A multi-regional layout that enhances growth elasticity [4] - A high-end product mix that improves profitability and brand barriers [4] - As the industry transitions from an expansion phase to a refined competition phase, the company's systemic competitiveness in supply chain, internationalization, and brand matrix will be key to its sustained growth capability [4]

Core Insights - H&H International Holdings Limited reported a revenue of 10.805 billion yuan for the first nine months of 2025, representing a year-on-year growth of 12.3% [1] - The company’s three core business segments—Adult Nutrition and Care (ANC), Infant Nutrition and Care (BNC), and Pet Nutrition and Care (PNC)—all experienced growth, with China remaining the primary revenue source, accounting for 71.0% of total revenue, up 20.6% year-on-year [1] - The company aims to enhance scientific innovation investments to drive growth in adult nutrition, infant formula, and pet nutrition products while optimizing its capital structure [3] Business Segment Performance - ANC segment achieved a revenue of 5.24 billion yuan, growing by 6.0% year-on-year, with Swisse in China growing by 15.7%, driven mainly by e-commerce channels [1][2] - BNC segment revenue reached 3.97 billion yuan, up 24.0% year-on-year, with sales of infant formula in mainland China increasing by 35.2%, outperforming the overall market [2] - PNC segment generated 1.59 billion yuan in revenue, reflecting an 8.2% year-on-year growth, supported by an upgrade in pet consumption structure [2] Financial Health - The company has optimized its capital structure by repaying 300 million yuan (equivalent) of USD syndicated loans ahead of schedule, reducing debt levels and improving financing efficiency [2] - As of the end of September, the company maintained a cash reserve of 1.74 billion yuan, ensuring stable overall liquidity [2]

Report Industry Investment Rating - Not provided in the document Core Viewpoints - The LGFV space remained stable, with higher-yielding issues tightening due to HF demand, and overall two-way flows skewed towards buying from RMs, especially for onshore AAA-guaranteed CNH issues [3] - BTSDF is on track to achieve its FY25 revised revenue target based on the 9M25 run-rate. The conviction level of BTSDF 9.125 07/24/28 is now lower, so the recommendation changes to neutral, and the switch is made to FOSUNI 8.5 05/19/28 for better carry [4] - Bangkok Bank's new BBLTB 30s and BBLTB 35s are expected to have FVs of T+80 - 85bps and T+95 - 100bps, respectively [4][8] - H&H's credit profile is improving, and it is on track to achieve its FY25 revised revenue target. Its near-term refinancing risk is manageable [16][17][21] Summary by Directory Trading Desk Comments - Yesterday, the MEITUA curve and TW lifer NSINTW/FUBON widened by 2 - 5bps. There were two-way flows on CCAMCL Perp and block two-way trading on CDBFLC 35. Chinese and global funds sold HK bank SHCMBK/DAHSIN/BNKEA/NANYAN T2s [2] - The NWDEVL complex rose 1.4 - 2.9pts. BTSDF 9.125 07/24/28 was 0.1pt lower. In Chinese properties, VNKRLE 27 - 29 were down by 0.4 - 1.0pt, and FUTLAN 28/FTLNHD 26 - 27 were 0.1pt lower [2] - Japanese/Korean IG spaces were up to 5bps wider on financial and corporate bonds, but flows were balanced on JP bank FRNs. SOFTBK and RAKUTN bonds were down by 0.9 - 1.3pts. Yankee AT1s and insurance subs dropped by 0.3 - 0.5pt. In SEA, OCBCSP/BBLTB T2s traded 3 - 5bps wider, and ACPM 5 1/8 Perp lowered by 1.3pts. There were two-way flows on BSFR 35 in the Middle Eastern space [2] Macro News Recap - On Tuesday, S&P (-0.83%), Dow (-1.07%), and Nasdaq (-1.21%) were lower. The latest initial jobless claims were +232k, higher than the market expectation of +223k. UST yield was lower, with 2/5/10/30 year yields at 3.58%/3.70%/4.12%/4.74% [7] Desk Analyst Comments - Bangkok Bank plans to issue 5yr and 10yr Reg S/144A senior unsecured USD bonds. The FV of the new BBLTB 30s and BBLTB 35s is expected to be T+80 - 85bps and T+95 - 100bps, respectively, considering its existing curve [8] BBLTB Analysis - Bangkok Bank is the largest bank in Thailand by total assets as of Sep'25, with a presence in 14 international markets. Its loan book is more diversified geographically than local peers, and it has the largest exposure to corporate and lowest to SME and retail [11] - In 9M25, Bangkok Bank showed resilient profitability, stable asset quality, and strong capital adequacy. NIM declined to 2.81% from 3.05% in 9M24, and the cost-to-income ratio fell to 44.7% from 46.3%. ROA/ROE increased to 1.12%/8.99% from 1.03%/8.54% in 9M24 [12] - In 3Q25, Bangkok Bank's asset quality stabilized, with credit costs down to c1.5% from c1.6% in 2Q25. The gross NPL ratio rose to 3.3% as of Sep'25 from 3.2% as of Jun'25, mainly due to a shrink in the loan book. NPL coverage ratio was 294% as of Sep'25 [13] - Bangkok Bank's capital buffers remain ample, with a standalone CET1 ratio of 19.6% as of Sep'25, well above the 8.0% regulatory minimum. The net reduction in CAR from redeeming USD750mn AT1 was mitigated by issuing USD1bn T2 bonds in Mar'25 [15] BTSDF Analysis - Based on the 9M25 run-rate, BTSDF is on track to achieve its FY25 revised revenue target. The conviction level of BTSDF 9.125 07/24/28 is now lower after moving up c5pts since the buy recommendation in Jan'25, so the switch is made to FOSUNI 8.5 05/19/28 [4][16] H&H Analysis - H&H's 9M25 revenue increased by 12.0% yoy to RMB10.8bn, with all business segments growing. Mainland China remained the largest market, contributing 71.0% of revenue in 9M25, up from 65.9% in 9M24 [17] - The ANC segment grew 5.2% yoy in 9M25, driven by Swisse's performance in mainland China, especially in cross-border e-commerce and Douyin channels [18] - The BNC segment grew 24.0% yoy in 9M25, mainly due to a 35.2% yoy increase in mainland China IMF sales, reaching a market share of 16.4% as of Sep'25. The decline in pediatric probiotic and nutritional supplements narrowed [19] - The PNC segment grew 8.2% yoy in 9M25, due to Zesty Paws' growth in North America, partially offset by Solid Gold's decline in North America [20] - As of Sep'25, H&H held RMB1.7bn of cash, up from RMB1.6bn as of Dec'24. It has been proactive in debt management, and its near-term refinancing risk is manageable, with no major debt maturities until 2027 [21] - H&H targets to reduce net debt/adj. EBITDA to 3.7x by Dec'25 from 3.9x as of Jun'25 and considers an 80% RMB share of total debt as an optimal currency mix [22] Offshore Asia New Issues - New issued: The Hong Kong Mortgage Corporation issued USD1000mn 5yr bonds with a 3.875% coupon at T+20 [25] - In the pipeline: Bangkok Bank plans to issue 5yr and 10yr bonds at T+115 and T+130; the Government of Indonesia plans 5yr and 10yr bonds at 4.8% and 5.3%; SMBC Aviation Capital Finance plans a 10yr bond at T+145 [26] News and Market Color - There were 161 credit bonds issued onshore yesterday with an amount of RMB193bn. Month-to-date, 1,188 credit bonds were issued with a total amount of RMB1,299bn, a 35.4% yoy increase [27] - S&P upgraded Marubeni Corp by one notch to A- from BBB+ with a stable outlook [27] Company News - NWD increased the cap on exchange offers to USD1.79bn from USD1.6bn, added an early tender date on 25 Nov'25 and an extra early payment date on 1 Dec'25 [33] - PDD Holdings 9M25 revenue was up 8.7% yoy to RMB307.9bn (cUSD43.4bn) [33] - POSCO's trading arm will acquire KRW1.3tn (cUSD860mn) worth of shares in Singapore's AGPA [33] - SoftBank's USD6.5bn bid for Ampere secured HSR early termination [33] - A former TSMC executive was probed by Taiwan over potential technology transfer and received TWD147bn (cUSD4.7bn) in government subsidies over 21 months [33] - Moody's placed West China Cement under review for upgrade following a bond deal and tender offer [33] - Xiaomi 3Q25 revenue was up 22.3% yoy to RMB113.1bn (cUSD16bn) [33]

Core Viewpoint - H&H International Holdings (01112) reported a 5% year-on-year increase in total revenue for H1 2025, amounting to 7.019 billion yuan, with adjusted comparable EBITDA decreasing by 3% to 1.101 billion yuan, and adjusted comparable net profit increasing by 5% to 363 million yuan. The company is expected to see EPS of 0.79, 1.05, and 1.30 yuan for 2025-2027, with a "Buy" investment rating assigned by Huaxin Securities [1]. Revenue and Profitability - The company experienced a year-on-year revenue increase, with a notable improvement in gross margin. The gross margin for H1 2025 rose by 2 percentage points to 62.53%, driven by higher margins in adult and pet nutrition and care products, along with product mix optimization [1]. - The proportion of sales and distribution/administrative expenses relative to revenue increased by 3 percentage points and decreased by 0.4 percentage points to 42.33% and 5.68%, respectively, due to changes in the channel mix for adult nutrition and care products in mainland China and investments in new market expansion strategies [1]. - Adjusted comparable EBITDA margin and adjusted comparable net profit margin decreased by 1 percentage point and 0.02 percentage points to 15.68% and 5.17%, respectively, primarily due to high base effects from the previous year and increased selling expenses [1]. Business Segment Performance - The adult nutrition and care products segment saw a 5% year-on-year revenue increase to 3.439 billion yuan, largely attributed to the outstanding performance of Swisse's innovative anti-aging product line, which grew by 39% compared to the benchmark [2]. - Revenue from infant nutrition and care products increased by 3% year-on-year to 2.501 billion yuan, driven by effective e-commerce channel development and new mother education initiatives in specialty stores. The company successfully transitioned its products to meet new national standards, with the market share of its premium infant formula brand reaching a historical high of 15.9% [2]. - The pet nutrition and care products segment experienced a 10% year-on-year revenue increase to 1.079 billion yuan, with gross margin rising by 12 percentage points to 58.70%. This growth was supported by deepened partnerships in North America and the ongoing high-end upgrade of Solid Gold in mainland China, leading to significant improvements in profitability [2]. Regional and Channel Insights - Revenue from mainland China increased by 9% year-on-year to 4.936 billion yuan, driven by strong growth in adult nutrition and care products and rapid channel expansion. Cross-border e-commerce revenue grew by 18%, with Douyin channel revenue surging by 80%, becoming a key growth engine [3]. - Revenue from Australia and New Zealand decreased by 18% to 801 million yuan, primarily due to a decline in corporate purchasing business [3]. - North American revenue increased by 6% to 862 million yuan, benefiting from the popularity of premium pet nutrition products and a growing pet population, with major retailers like Amazon, Walmart, and PerSmart performing well [3]. - Other regions saw a 17% year-on-year revenue increase to 420 million yuan, with strong growth in the Asian expansion market [3].